ETHY-001 demonstrated potent and durable TSHR target engagement from a single subcutaneous dose in healthy volunteers - ...
CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) -- (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results